Article
Evaluation of MTAP and p16 immunohistochemical deficiency as surrogate marker for CDKN2A/B homozygous deletion in gliomas.
Pathology - 1 Jun 2023
Maragkou Theoni, Reinhard Stefan, Jungo Patric, Pasquier Baptiste, Neuenschwander Maja, Schucht Philippe, Vassella Erik, Hewer Ekkehard
Abstract excerpt
Homozygous deletion (HD) of the CDKN2A/B locus has emerged as an unfavourable prognostic marker in diffuse gliomas, both IDH-mutant and IDH-wild-type. Testing for CDKN2A/B deletions can be performed by a variety of approaches, including copy number variation (CNV) analysis based on gene array analysis, next generation sequencing (NGS) or fluorescence in situ hybridisation (FISH), but questions remain regarding...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.